166 related articles for article (PubMed ID: 22627696)
1. Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens.
Manier S; Barthelemy M; Fouquet G; Prod'homme C; Le Ray E; Samarcq P; Noel MP; Terriou L; Facon T; Cossment C; Boulanger F; Leleu X
Leukemia; 2012 Dec; 26(12):2552-4. PubMed ID: 22627696
[No Abstract] [Full Text] [Related]
2. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
[TBL] [Abstract][Full Text] [Related]
5. DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
Lemaire O; Attal M; Bourin P; Laroche M
Eur J Haematol; 2010 Mar; 84(3):276-7. PubMed ID: 19891699
[No Abstract] [Full Text] [Related]
6. [New treatment strategies for multiple myeloma].
Ozaki S
Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
[No Abstract] [Full Text] [Related]
7. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
[No Abstract] [Full Text] [Related]
9. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.
Popat R; Oakervee HE; Hallam S; Curry N; Odeh L; Foot N; Esseltine DL; Drake M; Morris C; Cavenagh JD
Br J Haematol; 2008 May; 141(4):512-6. PubMed ID: 18371113
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients.
Buda G; Orciuolo E; Carulli G; Galimberti S; Ghio F; Cervetti G; Pelosini M; Petrini M
Acta Haematol; 2013; 129(1):35-9. PubMed ID: 23107867
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
Chang WJ; Kang ES; Lee ST; Kim SH; Kim DW; Kim SJ; Kim K
Acta Haematol; 2014; 132(2):226-32. PubMed ID: 24732093
[TBL] [Abstract][Full Text] [Related]
14. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
15. Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma - comparison between two different induction regimens.
Ram R; Magen-Nativ H; Vidal L; Herscovici C; Peck A; Raanani P; Shpilberg O; Yeshurun M
Clin Transplant; 2012; 26(5):E549-54. PubMed ID: 23061765
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy for multiple myeloma].
Ishida T
Nihon Rinsho; 2007 Dec; 65(12):2280-4. PubMed ID: 18069273
[TBL] [Abstract][Full Text] [Related]
17. [Hematopoietic stem cell transplantation for multiple myeloma].
Kanda Y
Rinsho Ketsueki; 2009 Oct; 50(10):1420-6. PubMed ID: 19915350
[No Abstract] [Full Text] [Related]
18. 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
Minarik J; Sandecka V; Maisnar V; Gregora E; Spicka I; Starostka D; Plonkova H; Jarkovsky J; Walterova L; Wrobel M; Adamova D; Pika T; Melicharova H; Pour L; Radocha J; Pavlicek P; Straub J; Gumulec J; Bacovsky J; Adam Z; Scudla V; Hajek R
Leuk Res; 2013 Sep; 37(9):1063-9. PubMed ID: 23845888
[TBL] [Abstract][Full Text] [Related]
19. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
20. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
Leleu X; Fouquet G; Hebraud B; Roussel M; Caillot D; Chrétien ML; Arnulf B; Szalat R; Garderet L; Benajiba L; Pegourie B; Regny C; Royer B; Caulier A; Stoppa AM; Garciaz S; Touzeau C; Chaleteix C; Fermand JP; Loiseau HA; Facon T; Attal M; Moreau P;
Leukemia; 2013 Nov; 27(11):2242-4. PubMed ID: 23558525
[No Abstract] [Full Text] [Related]
[Next] [New Search]